FDA Extends Review of Novo Nordisk Drug

The US FDA has delayed its decision on Novo Nordisk's experimental hemophilia A drug to address manufacturing facility issues. The regulator raised no safety concerns, and the company still aims for a 2027 US launch.

Insights:
FILE PHOTO: The logo of pharmaceutical company Novo is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, September 21, 2026.

The United States Food and Drug Administration extended its review of Novo Nordisk's experimental hemophilia A drug over manufacturing site remediation issues, the Denmark-based drugmaker said on Friday. The delay impacts the application for denecimig, which targets adults and children with the rare blood-clotting disorder. The setback arrives as the company preserves its financial forecasts for 2026 while targeting a commercial launch in the first half of 2027.